louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02278003: A Pilot Study to Assess the Amnesic Properties of Propofol in Pediatric Patients
Official title: A Pilot Study to Assess the Amnesic Properties of Propofol in Pediatric Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pediatric Pateints
Amnesic Properties of Propofol
Keywords: Amnesic
Propofol
12-006
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
First posted: 2014-10-29
Enrollment: 69
Sex: ALL
Minimum age (years): 4
Maximum age (years): 14
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The goal of this study is to extend findings of propofol's effects on memory, as measured in volunteer research studies, to a clinical setting.


Eligibility criteria: Inclusion Criteria:

* The patient must be between 4 and 14 yrs of age and be undergoing a therapeutic or diagnostic procedure with or without sedation
* The patient must be able to comprehend and perform the task (naming pictures)
* The patient must have a minimum weight of 8 kg

Exclusion Criteria:

* Allergy to propofol (for those patients requiring sedation)
* Procedure of short duration (\< 15 min)
* Pregnancy
* Recent use (within 5 half-lives) of centrally acting medications that could affect concentration (e.g. diphenhydramine)

Primary outcomes:
measure: Sedation Threshold
timeFrame: 1 year
Secondary outcomes:
measure: Memory Threshold
timeFrame: 1 year
Other outcomes:
Locations:
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Eric Kelhoffer, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Veselis R, Kelhoffer E, Mehta M, Root JC, Robinson F, Mason KP. Propofol sedation in children: sleep trumps amnesia. Sleep Med. 2016 Nov-Dec;27-28:115-120. doi: 10.1016/j.sleep.2016.10.002. Epub 2016 Oct 22.
Clinical trial NCT00235703: Inter-Mountain Project on Antimicrobial Resistance and Therapy (IMPART)
Official title: Inter-Mountain Project on Antimicrobial Resistance and Therapy (IMPART)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Upper Respiratory Infections
Lead sponsor: University of Utah
Sponsor class: OTHER
First posted: 2005-10-10
Enrollment: 13000
Sex: ALL
Minimum age (years): 0
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: DEFINED_POPULATION
Time perspective: OTHER

Brief summary: This is a four-year study, funded by the Center for Disease Control and Prevention, related to antimicrobial resistance in rural communities. The project consists of four components: A) surveillance of antimicrobial resistance, B) promotion of appropriate antimicrobial drug prescribing, C) preliminary assessment of the environmental impact of antimicrobials, and D) the development of new antimicrobial products. Six rural communities in Utah, and six rural communities in Idaho are participating in this study. Component D is being performed by investigators at Harvard University, under the direction of Co-Investigator Roger Inouye.


Eligibility criteria: Inclusion Criteria:

* Suspected upper respiratory infection patients in 12 rural communities in Utah and Idaho

Exclusion Criteria:

-

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University of Utah
name: Matthew H. Samore, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Samore MH, Bateman K, Alder SC, Hannah E, Donnelly S, Stoddard GJ, Haddadin B, Rubin MA, Williamson J, Stults B, Rupper R, Stevenson K. Clinical decision support and appropriateness of antimicrobial prescribing: a randomized trial. JAMA. 2005 Nov 9;294(18):2305-14. doi: 10.1001/jama.294.18.2305.
Clinical trial NCT00699803: Study of T-PRED(TM) Compared to Pred Forte(R)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Cataract
Lead sponsor: Bausch & Lomb Incorporated
Sponsor class: INDUSTRY
First posted: 2008-06-18
Enrollment: 64
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Study of T-PRED(TM) compared to Pred Forte(R)


Eligibility criteria: Inclusion Criteria:

* 18 years of age

Exclusion Criteria:

* No active or adverse disease

Primary outcomes:
measure: Mean Aqueous Humor Prednisolone Acetate Concentration
timeFrame: 4 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Irvine
country: United States
facility: ISTA Pharmaceuticals, Inc.
state: California
Study officials:
affiliation: ISTA Pharmaceuticals, Inc.
name: Tim McNamara, PharmD
role: STUDY_DIRECTOR
References:
Clinical trial NCT05472103: Strategies for Musculoskeletal Symptoms Relieving and Ergonomy in Operating Room
Official title: Strategies for Musculoskeletal Symptoms Relieving and Ergonomy in Operating Room: a Prospective Clinical Trial. (MuSEO Study)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Musculoskeletal Pain
Surgery
Keywords: Musculoskeletal Pain; ergonomics; surgery
Lead sponsor: University of Palermo
Sponsor class: OTHER
First posted: 2022-07-25
Enrollment: 150
Sex: ALL
Minimum age (years): 25
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: It is well known that surgery requires not only a mental diligence, but also a real physical stress due to the need to assume particular postures for many hours or to repeat specific maneuvers several times. To this peculiar condition of surgical specialities over the years has been added the development of a series of instruments and technologies ranging from the use of loopes, to laparoscopic and robotic surgery. From the studies reported in the literature, between 74% and 87% of surgeons report symptoms related to their work with consequent effects on the quality of life (sleep loss, inability to carry out their recreational activities, etc.). Similarly, a lack of knowledge of the principles of ergonomics to be applied during the performance of one's surgical activity emerged, which could improve musculoskeletal symptoms with a positive effect on the quality of life of surgeons and consequently hoping for an improvement in professional performance.


Eligibility criteria: Inclusion Criteria:

* young surgeons

Exclusion Criteria:

* no consent to partecipate

Primary outcomes:
measure: rate of musculoskeletal symptoms
timeFrame: one month
Secondary outcomes:
measure: quality of life
timeFrame: one month
Other outcomes:
Locations:
city: Palermo
country: Italy
facility: Giuseppe Di Buono
state: PA
Study officials:
References:
Clinical trial NCT03432403: The Effect of EGD Scope Insertion on the Intracuff Pressure of a New, Modified LMA in Children
Official title: The Effect of Esophagogastroduodenoscopy Scope Insertion on the Intracuff Pressure of a New, Modified Laryngeal Mask Airway in Children
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Intracuff Pressure
Lead sponsor: Nationwide Children's Hospital
Sponsor class: OTHER
First posted: 2018-02-14
Enrollment: 200
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who weigh more than 30 kg who are undergoing an EGD and who are getting an LMA at Nationwide Children's Hospital.

Brief summary: The purpose of this current study is to compare changes of the intracuff pressure in the newly designed LMA with the older design LMA after insertion of an esophagogastroduodenoscopy (EGD) probe in pediatric patients and adolescents.


Eligibility criteria: Inclusion Criteria:

* Patients who weigh more than 30 kg
* Patients undergoing an EGD
* Patients getting an LMA

Exclusion Criteria:

* Patients who weigh less than 30 kg
* Use of an EGD probe with an OD greater than 14 mm
* Decision not to use an LMA for the procedure
* Tracheomalacia, bronchomalacia, or any other airway issues

Primary outcomes:
measure: Excessive intracuff pressure
timeFrame: as long as the LMA is in place in the OR with usually a max amount of time of 45 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Columbus
country: United States
facility: Nationwide Children's Hospital
state: Ohio
Study officials:
References:
Clinical trial NCT02007603: Concentration of Ampicillin / Sulbactam and Amoxicillin / Clavulanic Acid in the Blood During Renal Replacement Therapy in Longterm Renal Replacement Therapy Patients
Official title: Multiple-dose Pharmacokinetics of Ampicillin / Sulbactam and Amoxicillin / Clavulanic Acid During Haemodialysis in Longterm Haemodialysis Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Infection During Hemodialysis
Keywords: chronic hemodialysis
ampicillin
sulbactam
amoxicillin
clavulanic acid
pharmacokinetics
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
First posted: 2013-12-11
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study will be conducted to investigate the pharmacokinetics of ampicillin / sulbactam and amoxicillin/clavulanic acid during intermittent haemodialysis.


Eligibility criteria: Inclusion Criteria:

* Age \>18 years
* Suspected or proven bacterial infection requiring parenteral antibiotic therapy.
* Renal replacement therapy (HD)

Exclusion Criteria:

* Known hypersensitivity to ampicillin / sulbactam, amoxicillin / clavulanic acid or other beta-lactames, or severe hypersensitivity (anaphylactic reaction) to beta-lactam antibacterial agents.
* An expected survival of less than two days.
* Known pregnancy
* Co-administration of one of the following drugs: probenecid which cannot be discontinued for the duration of the study
* Ampicillin / sulbactam respectively amoxicillin / clavulanic acid as monotherapy for resistant species or fungal infections.
* Other reasons opposing the study participation on the discretion of the investigators.

Primary outcomes:
measure: Influence of hemodialysis on the area under concentration curve of ampicillin/sulbactam and amoxicillin / clavulanic acid plasma concentration levels.
timeFrame: day 15
Secondary outcomes:
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Medical University of Vienna
Study officials:
affiliation: Medical University of Vienna
name: Florian Thalhammer, Prof. MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06915103: A Case Report of NMDAR Encephalopathy
Official title: A Case Report of NMDAR Encephalopathy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Anti-NMDA Receptor Encephalitis
Mature Teratoma
Paraneoplastic Syndromes
Keywords: Magnetic Resonance
Gynecologic Surgery
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2025-04-08
Enrollment: 1
Sex: FEMALE
Minimum age (years): 34
Maximum age (years): 34
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Female patient presenting to emergency department with acute psychosis, characterized by alternating episodes of catatonia and mania, regressive speech, and inappropriate behaviors.

Brief summary: This case illustrates the clinical, radiologic, and histopathologic features of Anti-NMDAR encephalitis and underscores the importance of MRI in detecting ovarian teratomas when pelvic ultrasound is inconclusive.


Eligibility criteria: Inclusion Criteria:

* Suspected Anti-NMDA Encephalitis

Exclusion Criteria:

* Inability to consent

Primary outcomes:
measure: Anti-NMDA Encephalitis
timeFrame: 1 week
Secondary outcomes:
Other outcomes:
Locations:
city: Jacksonville
country: United States
facility: Mayo Clinic in Florida
state: Florida
Study officials:
affiliation: Mayo Clinic
name: Tri A. Dinh, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05793203: Single-center Prospective Study of Non-invasive Methods for the Diagnosis of Postoperative Complications in Liver Transplant Recipients
Official title: Single-center Prospective Study of Non-invasive Methods for the Diagnosis of Postoperative Complications in Liver Transplant Recipients
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Rejection Acute Hepatic
Transplant; Failure, Liver
Liver Dysfunction
Lead sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Sponsor class: OTHER
First posted: 2023-03-31
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients eligible for liver transplantation

Brief summary: A lot of different early and late complications may occur after liver transplantation. They could be related to surgical procedure, to infectious diseases or immuno-mediated diseases (acute cellular rejection, ACR). Almost all of those complications are characterized by an elevation in liver enzymes (ALT, AST and GGT) and a decline of liver function tests (serum bilirubin and INR increase) possibly leading to early allograft disfunction (EAD). In this scenario there is a lack of biomarker that could predict the development of ACR and/or EAD.

The aim of this study is to explore the prognostic role of non-invasive instrumental and biological marker in the early post-transplant phase.


Eligibility criteria: Inclusion Criteria:

* Patients eligible for liver transplantation following National and International Guidelines

Exclusion Criteria:

* No agreement or inability to give informed consent

  * Re-transplant patients
  * Liver transplant in fulminant hepatitis

Primary outcomes:
measure: Early Allograft dysfunction (EAD)
timeFrame: 2 weeks from Liver transplantation
Secondary outcomes:
Other outcomes:
Locations:
city: Rome
country: Italy
facility: Fondazione Policlinico Universitario A. Gemelli IRCCS
Study officials:
affiliation: Catholic University of the Sacred Heart
name: Antonio Liguori, MD
role: STUDY_CHAIR
References:
Clinical trial NCT02123303: Orthostatic Hypotension Among Veterans
Official title: The Incidence of Orthostatic Hypotension Among Veterans
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hypotension, Orthostatic Hypotension
Keywords: Hypotension, Orthostatic Hypotension
Lead sponsor: James J. Peters Veterans Affairs Medical Center
Sponsor class: FED
First posted: 2014-04-25
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Maximum age (years): 89
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Any able-bodied veteran (able to independently stand for 10 minutes) that presents for a routine clinical visit or a neurological clinic visit at the James J. Peters VA Medical Center and does not have an acute illness or infection is eligible to participate in the study.

Brief summary: Orthostatic hypotension (OH) is defined as a fall in blood pressure when standing. Several different underlying diseases, conditions, or combinations of medicines may contribute to OH; therefore the cause of the condition varies among individuals. Some studies have shown that OH is associated with an increase in the rate of death, but it is not clear what role OH plays in increased morbidity. By studying what the prevalence of OH is in a generalized veteran population we expect increase clinical awareness of the degree of the problem so that patient care might be improved.


Eligibility criteria: Inclusion Criteria:

* Veterans
* Between the ages of 18 and 89

Exclusion Criteria:

* Current illness/infection
* Pregnant

Primary outcomes:
measure: Change in blood pressure from supine to standing.
timeFrame: Eval#1: 10min supine; Eval#2: 10min standing;
Secondary outcomes:
Other outcomes:
Locations:
city: Bronx
country: United States
facility: VA Medical Center, Bronx
state: New York
Study officials:
affiliation: James J. Peters VAMC
name: Jill M Wecht, EdD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06894303: Evaluation of Remote Programming of Cochlear Implants in Routine Cochlear Implant Follow-up
Official title: Evaluation of Remote Programming of Cochlear Implants in Routine Cochlear Implant Follow-up
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Cochlear Hearing Loss
Lead sponsor: Advanced Bionics AG
Sponsor class: INDUSTRY
First posted: 2025-03-25
Enrollment: 51
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Advanced Bionics adults CI users

Brief summary: This is a prospective and monocentric clinical investigation, non-interventional and non-randomized. The overall goal of this clinical study is to generate additional clinical data confirming the safety and efficacy of the remote programming functionality of Target CI version 1.5 and the AB Remote Support app. Hearing outcomes are expected to be similar whether a study subject's sound processor is programmed in the traditional method in the audiologist's office or whether programming is performed via remote fitting. Therefore, the study uses a non-inferiority design to determine whether sentence recognition in noise is no worse with remote fitting than in an in-office setting.


Eligibility criteria: Inclusion Criteria:

* Ability to provide informed consent
* Ability to give feedback on hearing impressions
* Aged 18 years of age or older
* Implanted with a HiResolution Bionic Ear System (HiRes 90K or HiRes 90K Advantage or HiRes Ultra or HiRes Ultra 3D) on at least one side

  * Group 1 - Unilateral: no hearing device except contralateral routing of signals (CROS) device on the contralateral side
  * Group 2 - Bilateral: implanted on both sides
  * Group 3 - Bimodal: hearing aid on the contralateral side
* Minimum of six months of cochlear implant experience
* Minimum of one month experience with a Naída CI M or Sky CI M sound processor
* Fluent in French language
* Ability to be tested via speech perception test in noise
* Smartphone user

Exclusion Criteria:

* Clinical presentation indicative of potential implanted device malfunction
* Unrealistic expectations regarding potential benefits, risks and limitations of the investigational device as determined by the Investigator
* Unwillingness or inability of subject to comply with all investigational requirements as determined by the Investigator

Pregnancy and breast-feeding are not exclusion criteria.

Primary outcomes:
measure: 50% SRT measured as signal to noise ratio in DB (French Matrix test in noise)
timeFrame: one-month chronic use of remotely fitted sound processor
Secondary outcomes:
measure: Score in the Lafon phoneme test in quiet
timeFrame: one-month chronic use of remotely fitted sound processor
Other outcomes:
Locations:
city: Paris
country: France
facility: Groupement Hospitalier Pitié Salpêtrière
Study officials:
References:
Clinical trial NCT05570903: A Prospective Observational Cohort Study of Awake Prone Position Ventilation Strategy in Patients With Acute Respiratory Failure
Official title: A Prospective Observational Cohort Study of Awake Prone Position Ventilation Strategy in Patients With Acute Respiratory Failure
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Acute Respiratory Failure
Lead sponsor: First Affiliated Hospital of Zhejiang University
Sponsor class: OTHER
First posted: 2022-10-07
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Acute and critical patients transferred from primary hospitals or admitted to emergency departments

Brief summary: Awake prone positioning has been used widely for patients with COVID-19.Many research results are not uniform on the key issue of whether the prognosis of patients can be improved，and most of the subjects were patients with SARS-CoV-2 infected who are not intubated.The investigators will conduct a prospective observational study on patients with acute respiratory failure induced by various causes to determine whether awake prone position can reduce the need to upgrade to invasive mechanical ventilation and improve the prognosis of patients compared with standard treatment.


Eligibility criteria: Inclusion Criteria:

* 1.Older than 17 years, admitted to the ICU;2.Patients with acute respiratory failure meet the following conditions：①Under the condition of breathing air at rest, PaO2 of subjects is lower than 60mmHg and/or PaCO2 is higher than 50mmHg; ②Under the support of COT and HFNC, PaO2/FiO2 of the subject is less than 250; ③ Under the support of NIV ;

Exclusion Criteria:

* 1.Refusing to cooperate with active treatment; 2.Immediate need for intubation as determined by the treating team.3Patients with hemodynamic instability and moderate to high dose of vasopressors (norepinephrine dose ≥ 0.15 mcg/kg/min)；4.Contraindication to PP (e.g. vomiting, abdominal wound, unstable pelvic/spinal lesions, pregnancy \>20/40 gestation, severe brain injury)；

Primary outcomes:
measure: Endotracheal intubation rate
timeFrame: 28 days
measure: Mortality
timeFrame: 28 days
Secondary outcomes:
measure: Total hours of prone position at day
timeFrame: 28 days
measure: Total number of prone sessions at day
timeFrame: 28 days
measure: Total days of prone positioning therapy
timeFrame: 28 days
measure: Non-invasive ventilation days
timeFrame: 28 days
measure: Change in the ROX-index 1-hour after first prone session
timeFrame: 1 hour
measure: Total length of stay in ICU and hospital
timeFrame: 28 days
Other outcomes:
Locations:
Study officials:
References: